These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 38795424

  • 1. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S, Sun L, Vakkalanka JP.
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [Abstract] [Full Text] [Related]

  • 2. Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit.
    Weiner SG, Little K, Yoo J, Flores DP, Hildebran C, Wright DA, Ritter GA, El Ibrahimi S.
    JAMA Netw Open; 2024 Jul 01; 7(7):e2423954. PubMed ID: 39037812
    [Abstract] [Full Text] [Related]

  • 3. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY.
    J Subst Abuse Treat; 2018 Feb 01; 85():90-96. PubMed ID: 28733097
    [Abstract] [Full Text] [Related]

  • 4. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG, Rosenheck RA.
    Addiction; 2019 Nov 01; 114(11):1992-1999. PubMed ID: 31307111
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails.
    Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA.
    JAMA Netw Open; 2024 Sep 03; 7(9):e2434704. PubMed ID: 39316401
    [Abstract] [Full Text] [Related]

  • 7. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ.
    Subst Abuse Treat Prev Policy; 2020 Sep 14; 15(1):69. PubMed ID: 32928272
    [Abstract] [Full Text] [Related]

  • 8. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B, El Shahawy O, Segoshi A, Moreno KP, Badiei B, Sarker A, Krawczyk N.
    J Addict Dis; 2021 Sep 14; 39(1):37-45. PubMed ID: 32835641
    [Abstract] [Full Text] [Related]

  • 9. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK, Xu KY, Salas J, Bedrick BS, Grucza RA.
    J Gen Intern Med; 2024 Jun 14; 39(8):1342-1348. PubMed ID: 38424347
    [Abstract] [Full Text] [Related]

  • 10. Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder.
    Lane BH, Lyons MS, Stolz U, Ancona RM, Ryan RJ, Freiermuth CE.
    Am J Emerg Med; 2021 Feb 14; 40():173-176. PubMed ID: 33243535
    [Abstract] [Full Text] [Related]

  • 11. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K, Slat S, Chen L, Macleod C, Bohnert A, Lagisetty P.
    J Subst Use Addict Treat; 2024 Aug 14; 163():209361. PubMed ID: 38703949
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.
    JAMA Netw Open; 2020 Feb 05; 3(2):e1920622. PubMed ID: 32022884
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C, Kramer CT, Terplan M, Fiscella K, Olson S, Voegtline K, Latkin C.
    JAMA Netw Open; 2022 Jan 04; 5(1):e2144369. PubMed ID: 35050354
    [Abstract] [Full Text] [Related]

  • 17. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R.
    J Clin Psychol; 2023 Dec 04; 79(12):2869-2883. PubMed ID: 37584532
    [Abstract] [Full Text] [Related]

  • 18. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
    Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE.
    JAMA Netw Open; 2019 Jun 05; 2(6):e196373. PubMed ID: 31251376
    [Abstract] [Full Text] [Related]

  • 19. Initiation of Buprenorphine in the Emergency Department: A Survey of Emergency Clinicians.
    Barkley A, Lander L, Dilcher B, Tuscano M.
    West J Emerg Med; 2024 Jul 05; 25(4):470-476. PubMed ID: 39028232
    [Abstract] [Full Text] [Related]

  • 20. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
    Barnett ML, Meara E, Lewinson T, Hardy B, Chyn D, Onsando M, Huskamp HA, Mehrotra A, Morden NE.
    N Engl J Med; 2023 May 11; 388(19):1779-1789. PubMed ID: 37163624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.